Current Status of Calcium Channel Blockers After Myocardial Infarction

  • Arthur J. Moss
Part of the Acute Coronary Care Updates book series (ACCU, volume 2)


Three calcium channel blocking agents—diltiazem, nifedipine, and verapamil—are approved by the Food and Drug Administration (FDA) for use in the United States. These agents are effective in the treatment of vasospastic angina, exertional and decubitus angina associated with obstructive atherosclerotic disease, and so called mixed angina with both vasospastic and obstructive components. All three of these agents reduce the frequency of angina pectoris, diminish the utilization of nitroglycerin, and increase the duration of time on treadmill testing before the development of angina in patients with coronary heart disease. Because calcium channel blockers have antianginal efficacy similar to the more established beta blocker class of drugs, the calcium antagonist drugs are being used extensively in acute coronary disease without prior evidence of safety and efficacy from appropriate clinical trials. Furthermore, each of the three calcium channel blocking agents has a different mechanism and spectrum of action, and the findings from one agent can not be extrapolated to the other agents in this class as safely as was done among the beta blockers. With this background, I will explore the current state of our knowledge and experience regarding the appropriate use of calcium blockers after myocardial infarction.


Acute Myocardial Infarction Beta Blocker Paroxysmal Atrial Fibrillation Calcium Blocker Vasospastic Angina 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Muller JE, Morrison J, Stone PH, Rude RE, Roser B, Roberts R, Pearle DL, Turi ZG, Schneider JF, Serfas DH, Tate C, Scheiner E, Sobel BE, Henenkens CH, Braunwald E. Nifedipine therapy for patients with threatened and acute myocardial infarction: a randomized, double-blind, placebo-controlled comparison. Circulation 69: 740–747, 1984.PubMedCrossRefGoogle Scholar
  2. 2.
    The Norwegian Nifedipine Group. Nifedipine in acute myocardial infarction. No influence on enzymatic infarct size. Circulation 68(III):22 (abstract), 1983.Google Scholar
  3. 3.
    The Danish Study Group on Verapamil in Myocardial Infarction. Verapamil in myocardial infarction. Eur Heart J 5:516–528, 1984.Google Scholar
  4. 4.
    Danish Multicenter Study Group on Verapamil in Myocardial Infarction. Am J Cardiol 54:24E-28E, 1984.CrossRefGoogle Scholar
  5. 5.
    Roberts R, Gibson RS, Boden WE, Theroux P, Strauss HD, Pratt CM, Gheorghiade M, Capone RJ, Crawford MH, Schlant RC, Kleiger RE, Perryman MB, the DRS Group. Prophylactic therapy with diltiazem prevents early reinfarction: a multicentered randomized double-blind trial in patients recovering from non-Q wave infarction. J Am Coll Cardiol 7:68A, 1986.CrossRefGoogle Scholar
  6. 6.
    Frishman WH, LeJemtel T. Electropharmacology of calcium channel antagonists in cardiac arrhythmias. Pace 5:402–407, 1982.PubMedGoogle Scholar
  7. 7.
    Theroux P, Taeymans Y, Waters D. Calcium antagonists: Clinical use in the treatment of angina. Drugs 25:179–187, 1983.CrossRefGoogle Scholar
  8. 8.
    Silverman K, Grossman W. Angina pectoris: Natural history and strategies for evaluation and management. N Engl J Med 310:1712–1722, 1984.PubMedCrossRefGoogle Scholar
  9. 9.
    Beta-Blocker Heart Attack Trial Research Group. Randomized trial of propranolol in patients with acute myocardial infarction. JAMA 247;1707–1714, 1982.CrossRefGoogle Scholar
  10. 10.
    The Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 304:801–807, 1981CrossRefGoogle Scholar

Copyright information

© Martinus Nijhoff Publishing, Boston 1987

Authors and Affiliations

  • Arthur J. Moss
    • 1
  1. 1.Department of MedicineUniversity of Rochester School of Medicine and DentistryRochesterUSA

Personalised recommendations